Advice
in the absence of a submission from the holder of the marketing authorisation:
vernakalant (Brinavess®) is not recommended for use within NHS Scotland.
Indication under review: Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults
• For non-surgery patients: atrial fibrillation ≤ 7 days duration
• For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice112KB (PDF)
Medicine details
- Medicine name:
- vernakalant (Brinavess)
- SMC ID:
- 1222/17
- Indication:
- Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults • For non-surgery patients: atrial fibrillation ≤ 7 days duration • For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
- Pharmaceutical company
- Cardiome UK Limited
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 February 2017